A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...
Press Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: The Biopharmaceutical Contract ...
Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...
Our fair value estimate for WuXi is HKD 24.60 per share. WuXi has been growing at a CAGR of 53.3% for the past eight years. Although its USD 20.5 billion total backlog revenue supports our growth ...
Armed with $115 million and a clinical-stage asset, another player is emerging in the increasingly crowded T cell engager ...
Role of Real-World Evidence (RWE) in Driving Pharmaceutical R&D Outsourcing Market Growth ...
Calling people "mentally ill" based on their sexual identity and referring to women as "household objects" will now be allowed in the context of political discussions on social media giant Meta's ...